OFF-LABEL USE OF LETERMOVIR FOR TREATMENT OF CYTOMEGALOVIRUS IN PAEDIATRIC PATIENTS REGARDLESS OF HSCT (ESPID 2025) - May 25, 2025 - Abstract #EV0096; Pres time: May 27, 2025; Location: E-POSTER AREA; "Letermovir was used as monotherapy in one patient and in combination with other CMV-directed treatment including Ganciclovir (n=1) or CMV specific intravenous immunoglobulin (n=2) in the remaining three patients. Three patients received HSCT at a later time point with continuation (n=2) or readministration (n=1) of letermovir (data not included). Conclusions/Learning Points Letermovir may be useful for CMV directed therapy in immunocompromised paediatric patients."
Clinical • Cytomegalovirus Infection • Infectious Disease
|
|
Martin Dusleag; Alexander Kober; Daniela S. Kohlfürst; Daniela Sperl; Volker Strenger
|